DK1133316T3 - Adenovirus-formulering til genterapi - Google Patents
Adenovirus-formulering til genterapiInfo
- Publication number
- DK1133316T3 DK1133316T3 DK99960405T DK99960405T DK1133316T3 DK 1133316 T3 DK1133316 T3 DK 1133316T3 DK 99960405 T DK99960405 T DK 99960405T DK 99960405 T DK99960405 T DK 99960405T DK 1133316 T3 DK1133316 T3 DK 1133316T3
- Authority
- DK
- Denmark
- Prior art keywords
- infectivity
- adenovirus
- gene therapy
- adenovirus formulation
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10860698P | 1998-11-16 | 1998-11-16 | |
| US13311699P | 1999-05-07 | 1999-05-07 | |
| PCT/US1999/027177 WO2000029024A1 (en) | 1998-11-16 | 1999-11-16 | Formulation of adenovirus for gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1133316T3 true DK1133316T3 (da) | 2009-05-25 |
Family
ID=26806075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99960405T DK1133316T3 (da) | 1998-11-16 | 1999-11-16 | Adenovirus-formulering til genterapi |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1977764A1 (de) |
| AT (1) | ATE421337T1 (de) |
| AU (1) | AU1729600A (de) |
| CA (1) | CA2350890C (de) |
| DE (1) | DE69940354D1 (de) |
| DK (1) | DK1133316T3 (de) |
| ES (1) | ES2323991T3 (de) |
| WO (1) | WO2000029024A1 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001023001A2 (en) * | 1999-09-29 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Rapid peg-modification |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| GB2408750B (en) * | 2003-12-02 | 2008-12-10 | Arthur A Codd | Preservation of biological material |
| DE602005015332D1 (de) | 2004-02-23 | 2009-08-20 | Crucell Holland Bv | Verfahren zur Reinigung von Viren |
| DE602005026005D1 (de) * | 2004-06-14 | 2011-03-03 | Ishihara Sangyo Kaisha | Gefriergetrocknete zusammensetzung aus einer inaktivierten virushülle mit membranfusionsaktivität |
| ES2317517T5 (es) | 2005-04-11 | 2016-01-21 | Crucell Holland B.V. | Purificación de virus usando ultrafiltración |
| CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| RU2541784C2 (ru) | 2006-11-07 | 2015-02-20 | Санофи Пастер Байолоджикс Ко. | Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения |
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| EA023816B1 (ru) | 2010-02-15 | 2016-07-29 | Круселл Холланд Б.В. | СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26 |
| ES2757591T3 (es) | 2010-03-31 | 2020-04-29 | Stabilitech Biopharma Ltd | Estabilización de partículas virales |
| CN102892427A (zh) | 2010-03-31 | 2013-01-23 | 稳定性科技有限公司 | 用于稳定病毒颗粒、多肽或生物材料的赋形剂 |
| DK2552410T3 (en) | 2010-03-31 | 2019-02-18 | Stabilitech Biopharma Ltd | PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES |
| FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
| BR112013005049A2 (pt) * | 2010-09-02 | 2016-05-31 | Sanofi Pasteur | estabilizador para a preparação de uma composição vacina da pólio seca injetável |
| CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| TW201233803A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
| JP6034798B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク，インコーポレーテッド | 液体ウイルス製剤 |
| RU2013143149A (ru) * | 2011-02-24 | 2015-03-27 | Пэксвэкс, Инк. | Составы, пригодные для вакцин, получаемых сушкой распылением |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| SG11201405228VA (en) | 2012-03-12 | 2014-11-27 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
| CN103316356B (zh) * | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
| CN105431169B (zh) | 2012-03-22 | 2019-04-02 | 扬森疫苗与预防公司 | 抗rsv疫苗 |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| CN102755325B (zh) * | 2012-07-04 | 2013-05-29 | 深圳信立泰药业股份有限公司 | 一种头孢西丁钠药物组合物、其粉针剂及其制备方法 |
| EA035522B1 (ru) | 2013-04-25 | 2020-06-29 | Янссен Вэксинс Энд Превеншн Б.В. | Стабильные растворимые f-полипептиды rsv в конформации "до слияния" |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| PT3046536T (pt) * | 2013-09-19 | 2019-02-25 | Janssen Vaccines & Prevention Bv | Formulações de adenovírus melhoradas |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| JP2018510160A (ja) * | 2015-03-20 | 2018-04-12 | ブルーバード バイオ， インコーポレイテッド | ベクター製剤 |
| EP3283634B1 (de) | 2015-04-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Rekombinantes adenovirus mit expression von zwei transgenen mit einem bidirektionalen promotor |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| EP3821906A1 (de) | 2015-07-07 | 2021-05-19 | Janssen Vaccines & Prevention B.V. | Impfstoff gegen rsv umfassend eines modifizierten f polypeptide |
| CN105219645B (zh) * | 2015-11-06 | 2018-09-25 | 南京农业大学 | 一种微生物保护剂及其应用 |
| IL262109B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
| PE20190420A1 (es) | 2016-04-05 | 2019-03-19 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas |
| MY194419A (en) | 2016-05-30 | 2022-11-30 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| EP3484506A1 (de) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv-impfstoffe |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| EP3624844A1 (de) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| MX2020002876A (es) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Metodo para la induccion segura de inmunidad contra el vsr. |
| CN108703952B (zh) * | 2018-08-16 | 2021-05-07 | 张志刚 | 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用 |
| AR118734A1 (es) * | 2019-04-19 | 2021-10-27 | Regenxbio Inc | Formulaciones y métodos de vectores de virus adenoasociados |
| KR20220054819A (ko) * | 2019-08-29 | 2022-05-03 | 아스테라스 세이야쿠 가부시키가이샤 | 유전자 변형 암용해 백시니아 바이러스 및 이의 사용 방법 |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥ａ型肝炎ワクチン |
| WO1993018790A1 (en) * | 1992-03-24 | 1993-09-30 | Csatary Laszlo K | Vaccine containing live virus for therapy of viral diseases and malignancies |
| US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| CA2158935A1 (en) * | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| JPH09508017A (ja) * | 1994-01-12 | 1997-08-19 | ジェネティック セラピー，インコーポレイテッド | レトロウイルスベクターの精製 |
| US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
| EP1760151B1 (de) * | 1996-11-20 | 2012-03-21 | Crucell Holland B.V. | Adenovirus-Zusammensetzungen erhältlich durch ein verbessertes Produktions- und Reinigungsverfahren |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| WO1999041416A2 (en) * | 1998-02-17 | 1999-08-19 | Schering Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
-
1999
- 1999-11-16 ES ES99960405T patent/ES2323991T3/es not_active Expired - Lifetime
- 1999-11-16 AT AT99960405T patent/ATE421337T1/de active
- 1999-11-16 DE DE69940354T patent/DE69940354D1/de not_active Expired - Lifetime
- 1999-11-16 CA CA2350890A patent/CA2350890C/en not_active Expired - Lifetime
- 1999-11-16 AU AU17296/00A patent/AU1729600A/en not_active Abandoned
- 1999-11-16 EP EP08006162A patent/EP1977764A1/de not_active Withdrawn
- 1999-11-16 WO PCT/US1999/027177 patent/WO2000029024A1/en active Application Filing
- 1999-11-16 DK DK99960405T patent/DK1133316T3/da active
- 1999-11-16 EP EP99960405A patent/EP1133316B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE421337T1 (de) | 2009-02-15 |
| EP1133316A1 (de) | 2001-09-19 |
| WO2000029024A9 (en) | 2000-11-02 |
| CA2350890A1 (en) | 2000-05-25 |
| CA2350890C (en) | 2014-07-08 |
| WO2000029024A1 (en) | 2000-05-25 |
| EP1977764A1 (de) | 2008-10-08 |
| AU1729600A (en) | 2000-06-05 |
| DE69940354D1 (de) | 2009-03-12 |
| EP1133316B1 (de) | 2009-01-21 |
| ES2323991T3 (es) | 2009-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1133316T3 (da) | Adenovirus-formulering til genterapi | |
| EA200100337A1 (ru) | Стабильные жидкие составы ботулинического токсина | |
| DK0722313T3 (da) | Viskoelastiske sammensætninger af fluorerede organiske forbindelser | |
| DK1117440T3 (da) | Farmaceutiske sammensætninger indeholdende paclitaxel | |
| DK0812198T3 (da) | Stabilisering af prostaglandinpræparater | |
| ATE253063T1 (de) | 5-ht1f-agonisten | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| HUP0002877A2 (hu) | Stabil inzulinkészítmények és eljárás előállításukra | |
| BR0009951A (pt) | Composição de higiene pessoal | |
| PT758248E (pt) | Formulacoes para o factor ix | |
| EE9800248A (et) | Külmkuivatatud, vesiikuleid sisaldav ultraheli kontrastaine, selle valmistamismeetod ning ladustamise ja transpordi meetod, ultraheli kontrastaine keskkond ja selle valmistamismeetod ning külmkuivatuse stabilisaatorite kasutamine | |
| CA2521909A1 (fr) | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee | |
| CY1105185T1 (el) | Σταθepα σκευασματα ινσουλινης | |
| BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
| BR0007201A (pt) | Composições incluindo agentes de preservação demalto-oligossacarìdeos reduzidos, e métodospara preservar um material | |
| DE60232271D1 (de) | Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen | |
| GT199900129A (es) | Formulaciones liquidas de pirimetanilo y metodos para su preparacion. | |
| WO2022109294A3 (en) | Rna stabilization | |
| ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. | |
| DE60009926D1 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| DE69928646D1 (de) | Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen | |
| DE69903666D1 (de) | Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen | |
| ES2173360T3 (es) | Agentes odoriferos y/o aromaticos. | |
| ID25478A (id) | Agonis 5-ht1f | |
| AU3548901A (en) | Veterinary compositions for the treatment of parasitic diseases |